ARGX argenx SE Stock Quote

ARGX [NASD]

Healthcare | Biotechnology | Netherlands

Index	-	P/E	-	EPS (ttm)	-1.73	Insider Own	-	Shs Outstand	47.11M	Perf Week	-3.39%
Market Cap	13.15B	Forward P/E	-	EPS next Y	-14.09	Insider Trans	-	Shs Float	47.03M	Perf Month	-8.94%
Income	-	PEG	-	EPS next Q	-3.04	Inst Own	54.78%	Short Float	2.34%	Perf Quarter	4.56%
Sales	-	P/S	-	EPS this Y	-171.80%	Inst Trans	-	Short Ratio	7.63	Perf Half Y	6.90%
Book/sh	11.95	P/B	23.36	EPS next Y	-10.80%	ROA	-	Target Price	304.30	Perf Year	86.10%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	103.75 - 312.06	Perf YTD	-5.06%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-10.52%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	169.13%	ATR	10.29
Employees	186	Current Ratio	-	Sales Q/Q	16.10%	Oper. Margin	-	RSI (14)	44.98	Volatility	2.93% 2.93%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	1.11	Prev Close	282.17
Shortable	Yes	LT Debt/Eq	-	Earnings	Oct 22 BMO	Payout	-	Avg Volume	144.43K	Price	279.22
Recom	2.10	SMA20	-4.81%	SMA50	-0.89%	SMA200	19.54%	Volume	160,668	Change	-1.05%

Jan-04-21

Downgrade

Guggenheim

Buy → Neutral

Aug-25-20

Initiated

Raymond James

Outperform

$257

Aug-19-20

Downgrade

Evercore ISI

Outperform → In-line

Jul-29-20

Initiated

H.C. Wainwright

Neutral

$272

Feb-10-20

Initiated

BofA/Merrill

Buy

Nov-05-19

Initiated

Credit Suisse

Neutral

$137

Oct-31-19

Upgrade

William Blair

Mkt Perform → Outperform

Oct-22-19

Initiated

JP Morgan

Overweight

$167

Sep-27-19

Initiated

Wells Fargo

Market Perform

Sep-16-19

Resumed

Cowen

Outperform

Jun-28-19

Initiated

Robert W. Baird

Outperform

Jan-18-19

Resumed

SunTrust

Buy

Jan-04-19

Initiated

Morgan Stanley

Overweight

Dec-17-18

Initiated

Goldman

Buy

Dec-14-18

Initiated

Wolfe Research

Outperform

Jun-29-18

Initiated

Nomura

Buy

$161

Apr-09-18

Initiated

SunTrust

Buy

$125

Jan-29-18

Reiterated

JMP Securities

Mkt Outperform

$74 → $87

Jan-08-21 01:00AM	argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline GlobeNewswire
Jan-07-21 08:20AM	The Daily Biotech Pulse: CureVac COVID-19 Vaccine Deal, Argenx Out-Licenses Neuromuscular Disorder Drug, Xencor's Oncology Collaboration Benzinga
Jan-06-21 04:01PM	argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China GlobeNewswire
Jan-04-21 01:00AM	argenx to Present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-19-20 09:32PM	Is ARGX A Good Stock To Buy Now According To Hedge Funds? Insider Monkey
Dec-14-20 10:12AM	AstraZenecas $39 Billion Takeout of Alexion Wins Tepid Wall Street Approval Barrons.com
Nov-23-20 01:00AM	argenx Enters Into Agreement To Acquire Priority Review Voucher GlobeNewswire
Nov-17-20 07:00AM	argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience PR Newswire
Nov-09-20 01:00AM	argenx to Participate in Upcoming Virtual Investor Conferences GlobeNewswire -6.04%
Nov-03-20 04:14PM	Halozyme Therapeutics Deals With Drug Giants Spark Stock To New High Investor's Business Daily
09:52AM	Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises Zacks
Oct-22-20 12:30PM	argenx SE to Host Earnings Call ACCESSWIRE
07:16AM	Recap: argenx Q3 Earnings Benzinga
01:00AM	argenx Reports Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
Oct-15-20 01:00AM	argenx to Report Third Quarter 2020 Financial Results and Business Update on October 22, 2020 GlobeNewswire
Oct-06-20 08:24AM	The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation Benzinga
02:00AM	argenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships GlobeNewswire
Oct-05-20 01:00AM	argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific Session GlobeNewswire
Sep-16-20 04:53PM	argenx SE (ARGX): Hedge Fund Interest Inching Up Insider Monkey
Sep-02-20 01:00AM	argenx Management to Present at Upcoming Virtual Investor Conferences GlobeNewswire
Aug-04-20 01:00AM	argenx to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire
Jul-30-20 01:00AM	argenx reports half year 2020 financial results and provides second quarter business update GlobeNewswire -6.04%
Jul-29-20 01:46PM	Earnings Preview: argenx Benzinga
Jul-20-20 12:15PM	Did Hedge Funds Make The Right Call On argenx SE (ARGX) ? Insider Monkey
Jul-01-20 09:24AM	argenx (ARGX): Strong Industry, Solid Earnings Estimate Revisions Zacks
Jun-15-20 11:09AM	Is argenx SE (ARGX) A Good Stock To Buy? Insider Monkey
Jun-01-20 04:00PM	argenx announces closing of global offering GlobeNewswire
May-29-20 01:00AM	argenx announces full exercise of underwriters option to purchase additional ADSs GlobeNewswire
May-28-20 12:15AM	argenx raises $750 million in gross proceeds in a global offering GlobeNewswire
May-27-20 10:08AM	Biotech Stock Roundup: REGN's Stake Buyback, INO, NVAX's Coronavirus Updates & More Zacks
10:08AM	argenx Up on Positive Data from Pivotal Efgartigimod Study Zacks
07:25AM	The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas Benzinga
May-26-20 04:01PM	argenx announces launch of proposed global offering GlobeNewswire +34.29%
12:57PM	Here's Why argenx Stock Is Soaring Today Motley Fool
01:00AM	argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis GlobeNewswire
May-14-20 03:30PM	argenx SE (ARGX) Q1 2020 Earnings Call Transcript Motley Fool
01:00AM	argenx reports first quarter 2020 financial results and provides business update GlobeNewswire
May-12-20 09:52AM	Halozyme (HALO) Q1 Earnings and Revenues Miss Estimates Zacks
May-11-20 05:22AM	The argenx (EBR:ARGX) Share Price Gained 1374% And Shareholders Are Jubilant Simply Wall St.
May-08-20 11:46AM	7 Strong Buy Healthcare Stocks to Buy Now InvestorPlace
Mar-22-20 10:18PM	argenx SE (ARGX): Hedge Funds In Wait-and-See Mode Insider Monkey
Feb-27-20 08:09AM	Top Ranked Momentum Stocks to Buy for February 27th Zacks
01:00AM	argenx reports full year 2019 financial results and provides fourth quarter business update GlobeNewswire
Feb-26-20 08:57AM	Why Earnings Season Could Be Great for argenx (ARGX)? Zacks
Feb-09-20 03:01AM	Our Take On argenx SE's (EBR:ARGX) CEO Salary Simply Wall St.
Jan-07-20 08:40AM	These 3 Healthcare Stocks Are Set to Soar in 2020, Says Cowen TipRanks
Dec-29-19 09:40PM	Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus Benzinga
Dec-07-19 08:02AM	Hedge Funds Are Warming Up To argenx SE (ARGX) Insider Monkey
Nov-22-19 03:22PM	3 Strong Buy Biotech Stocks to Watch After Stifel Healthcare Conference TipRanks
Nov-12-19 04:00PM	argenx announces closing of global offering GlobeNewswire
Nov-10-19 02:52AM	If You Had Bought argenx (EBR:ARGX) Stock Five Years Ago, You Could Pocket A 1527% Gain Today Simply Wall St.
Nov-08-19 01:00AM	argenx announces full exercise of underwriters option to purchase additional ADSs GlobeNewswire
Nov-06-19 10:45PM	argenx raises $484 million in gross proceeds in a global offering GlobeNewswire
Oct-24-19 01:00AM	argenx reports third quarter 2019 financial results and provides business update GlobeNewswire
Oct-14-19 10:14PM	Hedge Funds Are Dumping argenx SE (ARGX) Insider Monkey
Sep-25-19 03:34AM	Read This Before Buying argenx SE (EBR:ARGX) Shares Simply Wall St.
Sep-03-19 01:00AM	argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference GlobeNewswire
Aug-07-19 04:43AM	Is argenx SE's (EBR:ARGX) CEO Paid Enough Relative To Peers? Simply Wall St.
Aug-06-19 01:00AM	argenx to Present at 2019 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-01-19 01:00AM	argenx reports half year 2019 financial results and second quarter business update GlobeNewswire
Jul-25-19 01:00AM	argenx to report half year 2019 financial results and second quarter business update on August 1, 2019 GlobeNewswire
Jul-08-19 10:00AM	Here's Why Momentum Investors Will Love ARGENX SE-ADR (ARGX) Zacks
Jun-20-19 01:35PM	Heres What Hedge Funds Think About argenx SE (ARGX) Insider Monkey
Jun-05-19 08:37AM	How Does argenx SE (EBR:ARGX) Affect Your Portfolio Volatility? Simply Wall St.
May-22-19 07:34AM	The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study Benzinga
01:00AM	argenx announces pipeline expansion and argenx 2021 vision to build integrated immunology company at 2019 R&D Day GlobeNewswire
May-02-19 06:43PM	Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks GuruFocus.com
Apr-25-19 02:38PM	Did Hedge Funds Drop The Ball On argenx SE (ARGX) ? Insider Monkey
Apr-13-19 07:41AM	Want an insiders way to play IPOs? This fund has had outsize success with its strategy MarketWatch
Apr-03-19 05:35AM	Has argenx SE (EBR:ARGX) Got Enough Cash? Simply Wall St.
Feb-28-19 07:00AM	argenx SE ADR to Host Earnings Call ACCESSWIRE
Feb-04-19 01:00AM	argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology PR Newswire
01:00AM	argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology GlobeNewswire
Jan-23-19 07:55AM	Today's Research Reports on Trending Tickers: Editas Medicine and argenx ACCESSWIRE
Jan-22-19 01:52AM	Who Has Been Selling argenx SE (EBR:ARGX) Shares? Simply Wall St.
Dec-26-18 02:22PM	6 Valuable Pipeline Drugs With Upcoming Catalysts Benzinga +5.38%
Dec-03-18 04:09AM	Dutch firm argenx, J&J affiliate to collaborate on cancer therapy Reuters +13.49%
01:00AM	argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia GlobeNewswire
01:00AM	argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110) GlobeNewswire
Nov-01-18 09:15AM	argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60th American Society of Hematology Annual Meeting and Exposition GlobeNewswire +20.05%
Oct-25-18 02:04AM	Is argenx SEs (EBR:ARGX) Liquidity Good Enough? Simply Wall St.
01:00AM	argenx reports third quarter 2018 financial results and provides business update GlobeNewswire
Oct-09-18 01:00AM	argenx awarded 2.6 million VLAIO grant to explore new applications of ABDEG technology GlobeNewswire
Sep-21-18 04:01PM	argenx announces closing of U.S. public offering for gross proceeds of approximately $300.6 million GlobeNewswire
Sep-18-18 08:46PM	argenx raises approximately $300.6 million in gross proceeds in a U.S. public offering GlobeNewswire -6.90%
08:44AM	The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares Benzinga
Sep-17-18 04:21PM	argenx announces launch of proposed public offering in the United States GlobeNewswire
01:01AM	argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia GlobeNewswire
Sep-06-18 01:01AM	argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis GlobeNewswire
Aug-29-18 01:01AM	argenx receives feedback from Japan's PMDA on Phase 3 clinical trial and regulatory pathway for efgartigimod in generalized myasthenia gravis GlobeNewswire
Aug-22-18 10:50AM	Argenx Shares Up After AbbVie Exercises Option To License Immuno-Oncology Drug Benzinga
03:47AM	AbbVie doubles down on cancer project with biotech group Argenx Reuters
02:01AM	argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody GlobeNewswire
Aug-09-18 04:06PM	argenx to Present at 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-02-18 01:01AM	argenx reports second quarter business update and half-year 2018 financial results GlobeNewswire
Jul-26-18 01:06AM	argenx to host conference call & webcast to report second quarter business update and half year 2018 financial results on August 2, 2018 GlobeNewswire
Jul-24-18 04:01PM	argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation GlobeNewswire
Jul-17-18 01:01AM	argenx receives milestone payment from strategic collaboration with Shire GlobeNewswire
Jun-28-18 01:01AM	argenx receives second preclinical milestone payment under its development agreement with AbbVie GlobeNewswire
01:00AM	argenx receives second preclinical milestone payment under its development agreement with AbbVie GlobeNewswire

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.A.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience